@article {GAMBINI7361, author = {DONATELLA GAMBINI and ELISA LOCATELLI and UMBERTO GIANELLI and CLAUDIA BAREGGI and BARBARA GALASSI and ROBERTO VISINTIN and SARA MASSIRONI and PAOLO G. DELL{\textquoteright}ORTO and MAURIZIO TOMIROTTI}, title = {Sunitinib-induced Complete Response in Metastatic Renal Cancer Expressing Neuroendocrine Markers: A New Predictive Factor?}, volume = {34}, number = {12}, pages = {7361--7365}, year = {2014}, publisher = {International Institute of Anticancer Research}, abstract = {Background: To date, no predictive factors are recognized and applied in the therapeutic choice for metastatic renal cell carcinoma. Due to significant side-effects and costs, which are relevant issues in this setting, optimization of treatments has become a priority. Case Report: We herein report a case of complete remission of metastatic renal cell carcinoma after 1 year of treatment with sunitinib. Since pancreatic metastases were detected by a 68Ga-DOTA-NOC positron emission tomography, it was decided to perform a histological revision of the specimens, with immunohistochemical staining for neuroendocrine markers on the primary tumor. Conclusion: On the basis of the detection of neuroendocrine markers on the primary neoplasm, together with pancreatic metastases positive on a 68Ga-DOTA-NOC positron emission tomography (PET), we hypothesize and discuss about a potential role of specific neuroendocrine markers as predictive indicators of response to sunitinib (and allegedly to other target therapies) in the treatment of this neoplasm.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/34/12/7361}, eprint = {https://ar.iiarjournals.org/content/34/12/7361.full.pdf}, journal = {Anticancer Research} }